Eye Meds Now

 Quick Ophthalmic Drug Search

223 items found
INVELTYS (loteprednol etabonate (1%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Anti-inflammatory Corticosteroids
Indications/Usage:

Corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.


Typical Dosing:  

►Post-operative inflammation and pain following ocular surgery:

  • Shake for 1 – 2 seconds before using.
  • Instill 1 – 2 drops into the affected eye twice daily beginning the day after surgery and continuing throughout the first 2 weeks of the post-operative period.

How Supplied:  
  • Product not yet commercially available.
This medication was approved by the FDA in August 2018 but is not yet commercially available. Anticipated availability (2.8 mL bottles) in early 2019.

Preservatives:  

benzalkonium chloride


Storage:  
  • Store upright at 59° – 77°F (15° – 25°C).
  • Do not freeze.


ISOPTO CARPINE (pilocarpine hydrochloride (1%, 2%, or 4%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Miotics
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; management of acute angle-closure glaucoma; prevention of post-operative elevated IOP associated with laser surgery and induction of miosis.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension:

  • 1 drop (1%, 2%, or 4% solution) applied topically in the eye(s) up to 4 times daily. Pilocarpine-naïve patients should be started on the 1% concentration as higher concentrations are often not tolerated initially. The frequency of instillation and concentration of Isopto® Carpine are determined by the severity of the elevated IOP and miotic response of the patient.
  • To limit systemic exposure to pilocarpine, patients may be instructed to perform punctal occlusion for 2 minutes after instillation of Isopto® Carpine ophthalmic solution.

►Acute angle-closure glaucoma, initial management:

  • Prior to Isopto® Carpine use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia.
  • Apply 1 drop (1% or 2% solution) topically in the eye(s) up to 3 times over a 30-minute period.
  • If laser iridoplasty or iridomy is used to break the attack, 1 drop of Isopto® Carpine 4% should be administered prior to the procedure. Following laser iridoplasty, 1 drop of Isopto® Carpine 1% should be administered 4 times daily until an iridotomy can be performed.

►Post-operative elevated IOP associated with laser surgery, prevention:

  • 1 drop (1%, 2%, or 4% solution) (or 2 drops administered 5 minutes apart) should be applied topically in the eye(s) 15 – 60 minutes prior to surgery.

►Miosis:

  • 1 drop  (1%, 2%, or 4% solution) (or 2 drops administered 5 minutes apart) should be applied topically in the eye(s).

►Use with other topical ophthalmic medications:

  • May be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

►Use in pediatric patients:

  • In children < 2 years of age:
    • 1 drop of Isopto® Carpine 1% applied topically in the eye(s) 3 times daily.
  • Children ≥ 2 years of age should be dosed as for adults.
  • For the induction of miosis prior to goniotomy or trabeculotomy in children, 1 drop of Isopto® Carpine 1% or 2% should be applied topically in the eye 15 – 60 minutes prior to surgery.

How Supplied:  
  • 1% Ophthalmic solution:
    • 15 mL bottles
  • 2% Ophthalmic solution:
    • 15 mL bottles
  • 4% Ophthalmic solution:
    • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Protect from freezing.


ISTALOL (timolol maleate (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Beta Blocking Agents
Indications/Usage:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma: 

  • 1 drop in the affected eye(s) once a day in the AM.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles

Preservatives:  

benzalkonium chloride 


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


Assistance: Payment Assistance

JETREA (ocriplasmin (1.25 mg/mL) intravitreal solution)
Prescription
Injectable
Intravitreal
Other Medications
Indications/Usage:

Indicated for the treatment of symptomatic vitreomacular adhesion.


Typical Dosing:  

Symptomatic vitreomacular adhesion:

  • 0.125 mg (0.1 mL of the solution) administered by intravitreal injection to the affected eye once as a single dose:
    • For single-use ophthalmic intravitreal injection only.
    • Must only be administered by a qualified physician.
    • This formulation of JETREA does not require dilution.
  • Additional information for Preparation for Administration and Administration and Monitoring is in Notes below.

How Supplied:  
  • 0.375 mg/0.3 mL single-use vials (0.3 mL each)

Preservatives:  

None listed in package insert.


Storage:  
  • Store frozen at or below -4°F (-20°C).
  • Protect the vials from light by storing in the original package until time of use.


Assistance: Payment Assistance

KEFLEX (cephalexin monohydrate (250 mg; 500 mg; 750 mg) capsules)
Prescription
Oral
Capsules
Antibiotics
Indications/Usage:

Indicated for the treatment of skin and skin structure infections, such as presptal cellulitis, internal hordeolum, dacryocystitis, caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus and Streptococcus pyogenes.

This medication has a broad FDA approval for "skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Skin and skin structure infections:

  • Adults and patients  15 years of age: 
    • The usual dose is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered. Treatment is administered for 7 – 14 days. For more severe infections larger doses may be needed, up to 4 grams daily in 2 – 4 equally divided doses.
  • Children (> 1 year of age):
    • Recommended total daily dose is 25 – 50 mg/kg given in equally divided doses for 7 – 14 days. In the treatment of β-hemolytic streptococcal infections, duration of at least 10 days is recommended. In severe infections, a total daily dose of 50 – 100 mg/kg may be administered in equally divided doses.
  • Dosage adjustment is required in patients with severe and end stage renal disease (ESRD) defined as CrCl < 30 mL/min. 
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • 250 mg capsules
  • 500 mg capsules
  • 750 mg capsules

Note: Oral solution and tablets of cephalexin are also available. Refer to "Cephalexin" drug card for information on oral solution and tablets.


Preservatives:  

None listed in package insert.


Storage:  
  • Store at 77ºF (25ºC).
  • Excursions permitted to 59º –  86ºF (15º – 30ºC).
  • Store in a tight, light-resistant container.


KETOPROFEN (ketoprofen (25 mg) capsules)
Prescription
Oral
Capsules
NSAIDS
Indications/Usage:

Carefully consider the potential benefits and risks of ketoprofen capsules USP and other treatment options before deciding to use ketoprofen capsules USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (See WARNINGS in package insert).

Ketoprofen capsules USP are indicated for the management of pain.


Typical Dosing:  

Mild-to-moderate pain:

  • Usual dose is 25 – 50 mg every 6 – 8 hours as necessary.
  • A smaller dose should be utilized initially in small individuals, in debilitated or elderly patients, or in patients with renal or liver disease (See PRECAUTIONS in package insert).
  • A larger dose may be tried if the patient’s response to a previous dose was less than satisfactory, but doses above 75 mg have not been shown to give added analgesia.
  • Daily doses above 300 mg are not recommended because they have not been adequately studied. Because of its typical non-steroidal anti-inflammatory drug-side-effect profile, including as its principal adverse effect GI side-effects (See WARNINGS and ADVERSE REACTIONS in package insert), higher doses of ketoprofen capsules should be used with caution and patients receiving them observed carefully.

How Supplied:  
  • 25 mg capsules

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Keep tightly closed.
  • Store at 68° – 77°F (20° – 25°C).
  • Dispense in a tight, light-resistant container with a child-resistant closure (as required).


KETOROLAC (ketorolac tromethamine (0.5%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
NSAIDS
Indications/Usage:

Indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis and for the treatment of post-operative inflammation in patients who have undergone cataract extraction.


Typical Dosing:  

 ►Ocular itching due to seasonal allergic conjunctivitis, recommended:

  • Instill 1 drop into the affected eye(s) 4 times a day.

 Post-operative inflammation after cataract surgery, recommended:

  • Instill 1 drop into the affected eye(s) 4 times daily, beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the post-operative period.

►Use with other topical ophthalmic medications: ketorolac ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, alpha-agonists, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.


How Supplied:  
  • 3 mL bottles
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 77°F (15° – 25°C). 
  • Protect from light.


LACRISERT (hydroxypropyl cellulose (5 mg) ophthalmic insert)
Prescription
Topical
Ophthalmic Insert
Other Medications
Indications/Usage:

Indicated for patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. Indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions.

Also indicated for patients with: exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.


Typical Dosing:  

Moderate to severe dry eye syndromes:

  • 1 insert in each eye once daily is usually sufficient to relieve the symptoms associated with moderate to severe dry eye syndromes. Individual patients may require more flexibility in the use of LACRISERT; some patients may require twice daily use for optimal results.
  • Clinical experience with LACRISERT indicates that in some patients several weeks may be required before satisfactory improvement of symptoms is achieved.
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • 5 mg ophthalmic inserts

Preservatives:  

None listed in package insert.


Storage:  
  • Store below 86°F (30°C).


Assistance: Payment Assistance

LASTACAFT (alcaftadine (0.25%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Indicated for the prevention of itching associated with allergic conjunctivitis.


Typical Dosing:  

Itching associated with allergic conjunctivitis:

  • Instill 1 drop into each eye once daily.
  • If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.

How Supplied:  
  • 3 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


Assistance: Payment Assistance

LATANOPROST (latanoprost (0.005%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Prostaglandin Analogs
Indications/Usage:

Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Typical Dosing:  

►Elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, recommended.

  • Instill 1 drop in the affected eye(s) 1 time daily in the evening. If 1 dose is missed, treatment should continue with the next dose as normal.
  • The dosage should not exceed once daily; the combined use of 2 or more prostaglandins, or prostaglandin analogs including latanoprost ophthalmic solution is not recommended. It has been shown that administration of these prostaglandin drug products more than once daily may decrease the IOP lowering effect or cause paradoxical elevations in IOP.
  • Reduction of the IOP starts approximately 3 – 4 hours after administration and the maximum effect is reached after 8 – 12 hours.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.
  • Contact lenses should be removed prior to the administration of latanoprost ophthalmic solution, and may be reinserted 15 minutes after administration.

How Supplied:  
  • 2.5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Protect from light.
  • Store unopened bottle(s) under refrigeration at 36° – 46°F (2° – 8°C).
  • During shipment to the patient, the bottle may be maintained at temperatures up to 104°F (40°C) for a period not exceeding 8 days.
  • Once a bottle is opened for use, it may be stored at room temperature up to 77°F (25°C) for 6 weeks.


LATISSE (bimatoprost (0.03%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Other Medications
Indications/Usage:

Indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.


Typical Dosing:  

Hypotrichosis of the eyelashes:

  • Ensure the face is clean, makeup and contact lenses are removed.
  • Once nightly, place 1 drop on the disposable sterile applicator supplied with the package and apply evenly along the skin of the upper eyelid margin at the base of the eyelashes. 
  • The upper lid margin in the area of lash growth should feel lightly moist without runoff. Blot any excess solution runoff outside the upper eyelid margin with a tissue or other absorbent cloth.
  • Dispose of the applicator after one use. Repeat for the opposite eyelid margin using a new sterile applicator.
  • Do not reuse applicators and do not use any other brush/applicator to apply LATISSE®.
  • Do not apply to the lower eyelash line [See Warnings and Precautions (5.3, 5.4 in package insert) and Patient Counseling Information (17) in package insert].
  • Additional applications of LATISSE® will not increase the growth of eyelashes.
  • Upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level.

How Supplied:  
  • 3 mL bottles with 70 applicators
  • 5 mL bottles with 140 applicators

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 77°F (2° – 25°C).


Assistance: Payment Assistance

LEVAQUIN (levofloxacin (500 mg; 750 mg) tablets)
Prescription
Oral
Tablets
Antibiotics
Indications/Usage:

Indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.

This medication has a broad FDA approval for "uncomplicated skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "uncomplicated skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Uncomplicated skin and skin structure infections:

  • Adults: (CrCl  50 mL/min):
    • 500 mg once every 24 hours for 7 – 10 days.
  • Dosage adjustment in adults with renal impairment:
    • Administer LEVAQUIN® with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced.
    • No adjustment is necessary for patients with a CrCl  50 mL/min.
    • In patients with impaired renal function (CrCl < 50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance [See Use in Specific Populations (8.6) in package insert].
  • Consult package insert for additional information.

How Supplied:  
  • Tablets:
    • 500 mg tablets
    • 750 mg tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 59° – 86°F (15° – 30°C) in well-closed containers.


Assistance: Payment Assistance

LEVOCETIRIZINE (levocetirizine dihydrochloride (5 mg) tablets)
Over the Counter
Oral
Tablets
Antihistamines
Indications/Usage:

Used to temporarily relieve these symptoms due to hay fever or other respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Symptoms due to hay fever or other respiratory allergies:

  • Adults  65 years of age:
    • Ask a doctor.
  • Adults and children 12 – 64 years of age:
    • Take 1 tablet (5 mg) once daily in the evening.
    • Do not take more than 1 tablet (5 mg) in 24 hours.
    • ½ tablet (2.5 mg) once daily in the evening may be appropriate for less severe symptoms.
  • Children 6 – 11 years of age:
    • Take ½ tablet (2.5 mg) once daily in the evening.
    • Do not take more than ½ tablet (2.5 mg) in 24 hours.
  • Children < 6 years of age:
    • Do not use.
  • Individuals with kidney disease:
    • Do not use.

How Supplied:  
  • 5 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° –  25°C).


LEVOCETIRIZINE CHILDREN'S (levocetirizine dihydrochloride (2.5 mg/5 mL) oral solution)
Over the Counter
Oral
Oral Solution
Antihistamines
Indications/Usage:

Used to temporarily relieve these symptoms due to hay fever or other respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Symptoms due to hay fever or other respiratory allergies:

  • Adults  65 years of age:
    • Ask a doctor.
  • Adults and children 12 – 64 years of age:
    • Take 5 mL or 10 mL once daily in the evening depending upon severity of symptoms.
    • Do not take more than 10 mL in 24 hours.
  • Children 6 – 11 years of age:
    • Take 5 mL once daily in the evening.
    • Do not take more than 5 mL in 24 hours.
  • Children 2 – 5 years of age:
    • Take 2.5 mL once daily in the evening.
    • Do not take more than 2.5 mL in 24 hours.
  • Children < 2 years of age:
    • Do not use.
  • Individuals with kidney disease:
    • Do not use.

How Supplied:  
  • 2.5 mg/5 mL oral solution

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° –  25°C).


LEVOFLOXACIN (levofloxacin (250 mg; 500 mg; 750 mg) tablets; (25 mg/mL) oral solution)
Prescription
Oral
Oral Solution
Tablets
Antibiotics
Indications/Usage:

Indicated in adult patients for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes.

This medication has a broad FDA approval for "uncomplicated skin and skin structure infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "uncomplicated skin and skin structure infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Uncomplicated skin and skin structure infections:

  • Adults: (CrCl  50 mL/min):
    • 500 mg once every 24 hours for 7 – 10 days.
  • Dosage adjustment in adults with renal impairment:
    • Administer levofloxacin with caution in the presence of renal insufficiency. Careful clinical observation and appropriate laboratory studies should be performed prior to and during therapy since elimination of levofloxacin may be reduced.
    • No adjustment is necessary for patients with a CrCl  50 mL/min.
    • In patients with impaired renal function (CrCl < 50 mL/min), adjustment of the dosage regimen is necessary to avoid the accumulation of levofloxacin due to decreased clearance [See Use in Specific Populations (8.6) in package insert].
  • Consult package insert for additional information.

How Supplied:  
  • Tablets:
    • 250 mg tablets
    • 500 mg tablets
    • 750 mg tablets
  • Oral solution:
    • 25 mg/mL oral solution (100 mL, 200 mL, 480 mL bottles)

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Tablets should be stored at 59° – 86°F (15° – 30°C) in well-closed containers.
  • Oral solution should be stored at 77°F (25°C).
    • Excursions permitted to 59° – 86°F (15° – 30°C).


LORATADINE (loratadine (10 mg) capsules; (10 mg) tablets; (5 mg; 10 mg) tablets, orally disintegrating)
Over the Counter
Oral
Capsules
Oral Disintegrating Tablets
Tablets
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Runny nose; sneezing; itchy watery eyes; itching of the nose or throat:

  • Adults and children 6 years of age:
    • Do not take more than 1 tablet or capsule in 24 hours.
    • 1 tablet or capsule daily.
  • Children < 6 years of age:
    • Ask a doctor.
  • Individuals who have liver or kidney disease:
    • Ask a doctor.

How Supplied:  
  • Capsules:
    • 10 mg capsules
  • Tablets:
    • 10 mg tablets
  • Tablets, orally disintegrating
    • 10 mg tablets, orally disintegrating

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


LORATADINE CHILDREN'S (loratadine (10 mg) chewables; (5 mg/5 mL) oral solution)
Over the Counter
Oral
Chewable Tablets
Oral Solution
Antihistamines
Indications/Usage:

Used for the temporary relief of the following symptoms due to hay fever or other upper respiratory allergies: runny nose; sneezing; itchy, watery eyes; itching of the nose or throat.


Typical Dosing:  

►Runny nose; sneezing; itchy watery eyes; itching of the nose or throat:

  • Chewable tablets:
    • Adults and children 6 years of age:
      • Chew 2 tablets daily.
      • Do not take more than 2 tablets in 24 hours.
    • Children 2 to 6 years of age:
      • Chew 1 tablet daily.
      • Do not take more than 1 tablet in 24 hours.
    • Children < 2 years of age:
      • Ask a doctor.
    • Individuals who have liver or kidney disease:
      • Ask a doctor.
  • Oral solution:
    • Adults and children 6 years of age:
      • 10 mL (10 mg) daily.
      • Do not take more than 10 mL (10 mg) in 24 hours.
    • Children 2 to 6 years of age:
      • 5 mL (5 mg) daily.
      • Do not take more than 5 mL (5 mg) in 24 hours.
    • Children < 2 years of age:
      • Ask a doctor.
    • Individuals who have liver or kidney disease:
      • Ask a doctor.

How Supplied:  
  • Chewables:
    • 5 mg chewables
  • Oral solution:
    • 5 mg/5 mL solution

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


LOTEMAX (loteprednol etabonate (0.5%) ophthalmic gel; (0.5%) ophthalmic ointment; (0.5%) ophthalmic suspension)
Prescription
Topical
Gel
Ointment
Ophthalmic Suspension
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of post-operative inflammation and pain following ocular surgery.

LOTEMAX suspension is also indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.

Consult package insert for additional information.

This medication has a broad FDA approval for "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Post-operative inflammation and pain following ocular surgery:

  • Ophthalmic gel:
    • Invert closed bottle and shake once to fill tip before instilling drops.
    • Apply 1 – 2 drops into the conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period. 
  • Ophthalmic ointment:
    • Apply a small amount (approximately ½ inch ribbon) into the conjunctival sac(s) 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.
  • Ophthalmic suspension:
    • Shake vigorously before using.
    • Instill 1 – 2 drops into the conjunctival sac of the operated eye(s) 4 times daily, beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.

​​​​​​Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe and post-operative inflammation:

  • Ophthalmic suspension:
    • Shake vigorously before using.
    • Steroid responsive disease:
      • Instill 1 – 2 drops into the conjunctival sac of the affected eye(s) 4 times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour, if necessary.
      • Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after 2 days the patient should be re-evaluated.

How Supplied:  
  • Ophthalmic gel:
    • 5 g bottles
  • Ophthalmic ointment:
    • 3.5 g tubes
  • Ophthalmic suspension:
    • 5 mL bottles
    • 10 mL bottles
    • 15 mL bottles

Preservatives:  

benzalkonium chloride (ophthalmic gel, ophthalmic suspension); none listed in package insert (ophthalmic ointment).


Storage:  
  • Store upright at 59° – 77°F (15° – 25°C).
  • Do not freeze.
  • Use gel only if imprinted neckband is intact.
  • Do not use ointment if tamper evident skirt is visible on bottom of cap.
  • Do not use suspension if neckband imprinted with "Protective Seal" and yellow (mortar and pestle graphic) is not intact.


Assistance: Payment Assistance

LUCENTIS (ranibizumab (0.3 mg/0.05 mL; 0.5 mg/0.5 mL) injection)
Prescription
Injectable
Intravitreal
VEGF Inhibitors
Indications/Usage:

Indicated for the treatment of patients with: neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy; myopic choroidal neovascularization.


Typical Dosing:  

►General dosing information:

  • FOR OPHTHALMIC INTRAVITREAL INJECTION.
  • Vials: A 5-micron sterile filter needle (19-gauge x 1½ inch), a 1 mL Luer lock syringe and a 30-gauge x ½ inch sterile injection needle are needed but not included.

►Neovascular (wet) age-related macular degeneration (AMD):

  • 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
  • Although not as effective,  patients may be treated with 3 monthly doses, followed by less frequent dosing with regular assessment. In the 9 months after three initial monthly doses, less frequent dosing with 4 – 5 doses on average is expected to maintain visual acuity while monthly dosing may be expected to result in an additional average 1 – 2 letter gain. Patients should be assessed regularly [See Clinical Studies (14.1) in package insert].
  • Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Compared with continued monthly dosing, dosing every 3 months over the next 9 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average. Patients should be assessed regularly [See Clinical Studies (14.1) in package insert].

►Macular edema following retinal vein occlusion (RVO):

  • 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
  • Consult package insert for additional information.

►Diabetic macular edema (DME) and diabetic retinopathy (DR):

  • 0.3 mg (0.05 mL of 6 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

►Myopic choroidal neovascularization (mCNV):

  • 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to 3 months. Patients may be retreated if needed [See Clinical Studies (14.5) in package insert].

• Additional information for Dosage and Administration is in Notes below.


How Supplied:  
  • Prefilled syringes, single-use:
    • 0.3 mg/0.05 mL prefilled syringe (0.05 mL)
    • 0.5 mg/0.05 mL prefilled syringe (0.05 mL)
  • Vials, single-use:
    • 0.3 mg/0.05 mL vial (0.05 mL)
    • 0.5 mg/0.05 mL vial (0.05 mL)

Preservatives:  

None listed in package insert.


Storage:  
  • EACH CARTON IS FOR SINGLE-EYE USE ONLY.
  • Should be refrigerated at 36° – 46°F (2° – 8°C).
  • DO NOT FREEZE.
  • Do not use beyond the date stamped on the label.
  • Protect prefilled syringe and vials from light and store in the original carton until time of use.
  • Do not open prefilled syringe sealed tray until time of use.


Assistance: Payment Assistance

LUMIFY (brimonidine tartrate (0.025%) ophthalmic solution)
Over the Counter
Topical
Ophthalmic Solution
Ocular Decongestants/Vasoconstrictors
Indications/Usage:

Used to relieve redness of the eye due to minor eye irritations.


Typical Dosing:  

►Redness of the eye due to minor eye irritations:

  • Adults and children 5 years of age:
    • Instill 1 drop in the affected eye(s) every 6 – 8 hours.
    • Do not use more than 4 times daily.
    • Remove contact lenses before use.
    • Wait at least 10 minutes before re-inserting contact lenses after use.
    • If using other ophthalmic products while using this product, wait at least 5 minutes between each product.
    • To avoid contamination, do not touch tip of container to any surface.
    • Replace cap after each use.
  • Children < 5 years of age:
    • Consult a doctor.

How Supplied:  
  • 7.5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


223 items found